MiNK 413
Alternative Names: Agent-F6-BCMA-CAR-INKT; Allo-armored-BCMA-CAR-iNKT-MiNK Therapeutics; BCMA-CAR-iNKT; MiNK 413 BCMA CAR iNKT; MiNK-413Latest Information Update: 24 May 2024
At a glance
- Originator Agenus
- Developer Agenus; MiNK Therapeutics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; NKT cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple myeloma